Skip to main content
. 2018 Jan 17;9(8):8027–8041. doi: 10.18632/oncotarget.24261

Figure 1. In vitro antileukemia efficacy of dual JAK2 and mTOR inhibition in Ph-like B-ALL cell lines.

Figure 1

MHH-CALL4 and MUTZ-5 cells were treated with 0.25-0.8μM BBT594 (BBT), AZD2014 (AZD), or combinations for 72 h, then the numbers of viable cells were determined by CTG assay. The cell inhibition curves were plotted with the live cell number normalized to those of DMSO-treated controls: (A) MHH-CALL4 cells, (B) MUTZ-5 cells. Treated cells were fixed in 90% methanol and then stained with propidium iodine to determine the effects of the treatments on the cell cycle by flow cytometry: (C) MHH-CALL4 cells, (D) MUTZ-5 cells. The cells were stained with annexin V/DAPI to quantify cell apoptosis by flow cytometry: (E) MHH-CALL4 cells, (F) MUTZ-5 cells. * p<0.05, ** p<0.005, *** p<0.0005 as determined by unpaired Student t-test. (G, H) BaF/3 cells expressing the Ph-like B-ALL-associated JAK2 R683G parental (G) and ruxolitinib-“persistent” cells (H) were treated with 0.25-1.0μM BBT594, AZD2014 or the combination for 72 h, and cell viability was analyzed by CTG assay. The viability of cells treated was selected inhibitors was to those of DMSO-treated controls, and expressed as % viable cells.